Ke-Jun Wu

Ke-Jun Wu

Auto-generated profile, based on publicly available information

Ke-Jun Wu

Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2025 in Extracellular Vesicles and Circulating Nucleic Acids
Verified
Journal Article
Open access
PDF file
HWHai-Quan Wang
Hai-Quan Wang
LZLu Zhang
Lu Zhang
MLMing-Jie Li
Ming-Jie Li
RHRongquan He
Rongquan He
DQDi-Yuan Qin
Di-Yuan Qin
GCGang Chen
Gang Chen
Aim: The domain of exosomal circRNAs has seen rapid growth over the past few years, yet a thorough synthesis of the scholarly contributions has been lacking. This study employs bibliometric analysis to uncover the focal points and trends in exosomal circRNA research. Methods: We selected articles on exosomal circRNAs from the Web of Science Core Collection (WoSCC) and deployed VOSviewer for co-authorship and co-occurrence analysis. CiteSpace was tapped to calculate citation bursts for documents and keywords, generating a time-zone map. Additionally, the bibliometrix R package was employed to identify locally cited references and construct thematic maps and trend topics. Results: The exosomal circRNA research field has produced 767 articles over the past decade. China and Fudan University lead in publication counts, ranking first among countries and institutions, respectively. The journal with the highest number of publications and citations is Molecular Cancer . Zhang Wei and Li Yan are the top contributors and the most co-cited authors, respectively. Analysis of the results suggests that research related to the tumor microenvironment (TAM) may be a recent research hotspot. Among the latest keywords, terms such as microenvironment, macrophage, mesenchymal stem cells, and ceRNA appear frequently. The keyword with the most recent citation burst is ceRNA. The latest trend topic is the macrophage, and mesenchymal stem cell is identified as an emerging theme. Conclusion: This study elucidates the hotspots and trends in exosomal circRNA research through bibliometric analysis. Themes related to the TAM, especially directions involving macrophages, fibroblasts, and mesenchymal stem cells, will likely open a new chapter in exosomal circRNA research.

12 December 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
KWKe-Jun Wu
Ke-Jun Wu
LYLi-Hua Yang
Li-Hua Yang
DLDong-Ming Li
Dong-Ming Li
RHRong-Quan He
Rong-Quan He
DQDi-Yuan Qin
Di-Yuan Qin
XJXiao-Bo Jiang
Xiao-Bo Jiang
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide and shows significant heterogeneity. Cadherin 13 (CDH13) is ab


22 August 2026 in Hereditas
Verified
Journal Article
Open access
PDF file
KWKe-Jun Wu
Ke-Jun Wu
LWLei Wang
Lei Wang
YZYan-Ting Zhan
Yan-Ting Zhan
YTYu-Lu Tang
Yu-Lu Tang
MLMing-Jie Li
Ming-Jie Li
SCSi-Yan Chen
Si-Yan Chen
Background: Cholangiocarcinoma (CHOL) is a highly heterogeneous and aggressive malignancy that is frequently diagnosed at an advanced stage because of the lack of early biomarkers, resulting in a poor prognosis. Although ANAPC1 overexpression has been reported in other cancers, its role and regulatory mechanisms in CHOL remain insufficiently characterized. Objectives: To characterize ANAPC1 expression in CHOL, identify candidate upstream transcriptional regulators, and elucidate the associated functional programs and pathways. Methods: Multi-omics profiling was integrated with in-house immunohistochemical validation. Differential expression analyses, CRISPR-based functional screening, transcription-factor prioritization, ChIP-seq with epigenomic annotation, gene set enrichment analysis, spatial transcriptomics, and single-cell RNA-seq were conducted to investigate ANAPC1-associated regulatory mechanisms in CHOL.Structural modeling of predicted TEAD4–DNA complexes was additionally performed to assess the structural compatibility between TEAD4 and candidate ANAPC1 promoter motifs. Results: ANAPC1 was significantly overexpressed in CHOL at both the transcriptomic level (436 CHOL vs. 213 non-CHOL samples) and the protein level (66 CHOL vs. 99 non-CHOL tissues), with spatial enrichment in cholangiocytes. Public CRISPR dependency screening indicated that ANAPC1 loss was associated with reduced cellular fitness in several CHOL cell lines, including HUCCT1. Integrative analyses identified TEAD4 as a candidate upstream regulator of ANAPC1, and TEAD4 was upregulated in CHOL. Public ChIP-seq and epigenomic datasets across multiple cell lines, including HUCCT1, HepG2, BE2-C, and MDA-MB-231, suggested TEAD4 occupancy at the ANAPC1 locus, together with active chromatin features such as H3K27ac signals near the promoter region. Across several bulk transcriptomic datasets, TEAD4 and ANAPC1 showed positive expression associations of varying magnitude, whereas spatial transcriptomics indicated partially overlapping regional enrichment within malignant areas.Protein–DNA complex modeling of a predicted candidate TEAD4–ANAPC1 promoter DNA complex yielded an ipTM score of 0.71 and a pTM score of 0.62 for the top-ranked candidate promoter motif. GSEA identified positive enrichment of proliferation- and RNA-processing-related pathways and negative enrichment of several immune-related pathways within the ANAPC1-correlated transcriptomic profile. Single-cell analysis further localized ANAPC1 expression mainly to cholangiocytes and identified a statistically significant but extremely weak cell-level correlation with TEAD4. Conclusions: These findings support the hypothesis of a putative TEAD4–ANAPC1 regulatory relationship in CHOL based on integrative epigenomic, transcriptomic, spatial, and structural analyses. Direct experimental validation is required to determine whether TEAD4 functionally regulates ANAPC1 transcription in cholangiocarcinoma.